IMG_0314_Bangladesh, Head Agency

Recent Posts

• Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications H. A. Dowlat*, M. K. Kuhlmann, H. Khatami & F. J. Ampudia-Blasco
• How Safe Are Biosimilars? Implications of FDA and EMA Guidances and European Experience since 2006—Part 1
• How Safe Are Biosimilars? Implications of FDA and EMA Guidances and European Experience since 2006—Part 2
• Perceptions and realities of clinical safety of biosimilars – EU and US perspectives: Part 2
• Perceptions and realities of clinical safety of biosimilars – EU and US perspectives: Part 1